06938.HK_Providing professional financial news and data related to 06938.HK, committed to creating a comprehensive and efficient information access channel for users | NewTimeSpace

RIBOLIFE-B (06938.HK): Positive Phase IIa Results for Core Asset Vortosiran in CAD; Maximum FXI Activity Reduction Reaches 92%

Tags：

RIBOLIFE-B 06938.HK Clinical Data

2026-07-22

Ribo Life Science(06938.HK): Milestone Achieved with Selection of First Candidate Drug under Collaboration with Madrigal

Tags：

Ribo Life Science 06938.HK

2026-07-02

Ribo Life Science(06938.HK): Proposed Acquisition of 25.93% Equity Stake in Xingborun for RMB 70 Million

Tags：

Ribo Life Science 06938.HK

2026-07-01

Riborn Bio-B (06938.HK): Core Product Vortosiran Submits Phase 2b Clinical Trial Application for Venous Thromboembolism

Tags：

Riborn Bio-B 06938.HK Clinical Trial Application

2026-05-11

Raybow Biotech - B (6938.HK): Achieves Third Key Milestone in MASH R&D Collaboration with Boehringer Ingelheim

Tags：

Raybow Biotech-B 06938.HK BI R&D collaboration

2026-05-06

NewTimeSpace | Single-Day Drop Over 10%, Ribo Life(06938.HK) Approaches Offer Price within First Month of Listing

Tags：

Ribo Life 06938.HK NewTimeSpace

2026-02-03

Scan QR Code

Download App